fbpx

Safilo Board of Directors Approves 2017 Financial Results

Safilo Group’s net sales declined by 15.5% at constant currency compared to 2016, of which 12.3% was attributed to the change of the Gucci license to a supply agreement.

The Group’s net sales were 1047 million Euro in 2017, a contraction of 194 million Euro compared to last year. Sales of the “Going Forward Brand Portfolio” were reduced by 3.9%, while sales in the “Own Core Portfolio” increased slightly, in particular due to growth in emerging markets.

The Board of Directors also decided against proposing a dividend payout at the next Annual General Meeting.

Safilo posted a net loss of 47.1 million Euro in 2017, compared with the net profit of 15.4 million Euro in 2016.

Click here to read the full press release.

 

Featured Posts

EssilorLuxottica Oakley Enigma Ink and Enigma Mass eyewear models

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass, two lifestyle frames that redefine prescription and inspire wearers to express a whole other side of themselves.

Learn More
MIDO 2025

MIDO 2025: The 3-Day International Eyewear Show Concludes in Milan

More than 42,000 attendees from 168 countries, and 1,200 exhibitors, of those about 930 international, in 8 exhibit areas across 7 pavilions.

Read more
Voila Optik Jan-Feb 2025 WestGroupe Moleskine MO1263

A Fusion of Design and Eco-Conscious Practices with Moleskine Eyewear

MO-1263 in Tortoise Blue features a very classic tortoise pattern with blue temples.

Read more
Rolf CSE Award winner at Mido 2025

Rolf Wins CSE Award 2025

Austrian eyewear manufacturer Rolf received a prestigious award: the company has been honoured with the renowned CSE (Certified Sustainable Eyewear) Award for the second time in a row.

Read more
Fighting Blindness Canada

Phase 1 Study Finds Bone Marrow Stem Cells Safe as Potential Treatment for Retinitis Pigmentosa

A team of researchers at University of California Davis has published the results of a Phase 1 clinical trial testing stem cells therapy for retinitis pigmentosa (RP).

Read more
EssilorLuxottica Oakley Enigma Ink and Enigma Mass eyewear models

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass, two lifestyle frames that redefine prescription and inspire wearers to express a whole other side of themselves.

Learn More
MIDO 2025

MIDO 2025: The 3-Day International Eyewear Show Concludes in Milan

More than 42,000 attendees from 168 countries, and 1,200 exhibitors, of those about 930 international, in 8 exhibit areas across 7 pavilions.

Read More
Voila Optik Jan-Feb 2025 WestGroupe Moleskine MO1263

A Fusion of Design and Eco-Conscious Practices with Moleskine Eyewear

MO-1263 in Tortoise Blue features a very classic tortoise pattern with blue temples.

Read More
Rolf CSE Award winner at Mido 2025

Rolf Wins CSE Award 2025

Austrian eyewear manufacturer Rolf received a prestigious award: the company has been honoured with the renowned CSE (Certified Sustainable Eyewear) Award for the second time in a row.

Read More
Fighting Blindness Canada

Phase 1 Study Finds Bone Marrow Stem Cells Safe as Potential Treatment for Retinitis Pigmentosa

A team of researchers at University of California Davis has published the results of a Phase 1 clinical trial testing stem cells therapy for retinitis pigmentosa (RP).

Read More
EssilorLuxottica Oakley Enigma Ink and Enigma Mass eyewear models

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass, two lifestyle frames that redefine prescription and inspire wearers to express a whole other side of themselves.

Learn More
MIDO 2025

MIDO 2025: The 3-Day International Eyewear Show Concludes in Milan

More than 42,000 attendees from 168 countries, and 1,200 exhibitors, of those about 930 international, in 8 exhibit areas across 7 pavilions.

Read more
Voila Optik Jan-Feb 2025 WestGroupe Moleskine MO1263

A Fusion of Design and Eco-Conscious Practices with Moleskine Eyewear

MO-1263 in Tortoise Blue features a very classic tortoise pattern with blue temples.

Read more
Rolf CSE Award winner at Mido 2025

Rolf Wins CSE Award 2025

Austrian eyewear manufacturer Rolf received a prestigious award: the company has been honoured with the renowned CSE (Certified Sustainable Eyewear) Award for the second time in a row.

Read more
Fighting Blindness Canada

Phase 1 Study Finds Bone Marrow Stem Cells Safe as Potential Treatment for Retinitis Pigmentosa

A team of researchers at University of California Davis has published the results of a Phase 1 clinical trial testing stem cells therapy for retinitis pigmentosa (RP).

Read more
EssilorLuxottica Oakley Enigma Ink and Enigma Mass eyewear models

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass, two lifestyle frames that redefine prescription and inspire wearers to express a whole other side of themselves.

Learn More
MIDO 2025

MIDO 2025: The 3-Day International Eyewear Show Concludes in Milan

More than 42,000 attendees from 168 countries, and 1,200 exhibitors, of those about 930 international, in 8 exhibit areas across 7 pavilions.

Read more
Voila Optik Jan-Feb 2025 WestGroupe Moleskine MO1263

A Fusion of Design and Eco-Conscious Practices with Moleskine Eyewear

MO-1263 in Tortoise Blue features a very classic tortoise pattern with blue temples.

Read more
Rolf CSE Award winner at Mido 2025

Rolf Wins CSE Award 2025

Austrian eyewear manufacturer Rolf received a prestigious award: the company has been honoured with the renowned CSE (Certified Sustainable Eyewear) Award for the second time in a row.

Read more
Fighting Blindness Canada

Phase 1 Study Finds Bone Marrow Stem Cells Safe as Potential Treatment for Retinitis Pigmentosa

A team of researchers at University of California Davis has published the results of a Phase 1 clinical trial testing stem cells therapy for retinitis pigmentosa (RP).

Read more